You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The companies will work with labs to improve payors' understanding of the costs of performing PD-L1 testing and the value it provides to patient care.
The deal joins Indivumed's collection of tissue biospecimens and immunohistochemistry expertise with Ultivue's multiplex immunofluorescence platform.
The agency approved Agilent/Dako's PD-L1 IHC test for identifying TNBC patients who are most likely to respond to Keytruda and chemo.
Patients with discordant p16 and HPV markers fall into an intermediate risk group, research presented at the European cancer conference suggests.
The companies hope to combine their technologies to provide pharmaceutical customers with an end-to-end workflow for multiplex histological staining and imaging.
A new microbiome analysis uncovered cancer type-specific bacterial community features, along with intracellular bacteria in tumor and associated immune cells.
The company plans to offer four new products by the end of the year, including four targeted transcriptomic panels and IHC compatibility for Visium.
Though 10x will phase out its linked reads technology, it plans to introduce targeted RNA-seq for Chromium and FFPE sample compatibility for Visium.
The acquisition of immunohistochemistry services provider QualTek will augment Discovery's existing histopathology services, the company said.
The data add to growing evidence supporting the use of HER2 therapy across solid tumors, though researchers find a difficult path to a tissue-agnostic approval.
Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.
23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.